Navigation Links
Study Demonstrates Martek's Algal DHA Oil Improves Blood Triglyceride Lipid Levels
Date:9/4/2007

COLUMBIA, Md., Sept. 4 /PRNewswire-FirstCall/ -- Martek's life'sDHA(TM) from microalgae is effective in reducing the level of triglycerides in male hypertriglyceridemic patients, according to a study published in the current issue of The American Journal of Clinical Nutrition. In this study DHA (docosahexaenoic acid) alone was effective, without EPA (eicosapentaenoic acid), the other omega 3 commonly found in fish oil, in reducing triglycerides. Hypertriglyceridemia (high triglyceride levels) in men is associated with an increased risk of cardiovascular disease and metabolic syndrome.

The study, a randomized, parallel, double blind, placebo-controlled study that included 34 subjects, showed that supplementation with 3 grams DHA per day for 45 days resulted in a 24% decrease in fasting and postprandial triglyceride levels. This effect continued throughout the 90-day study period. Although LDL cholesterol increased by 13 percent, significant improvement was seen in the distribution of lipoprotein particle size. Researchers concluded that "DHA supplementation may improve cardiovascular health by lowering concentrations of triacylglycerols and small, dense LDL particles." The investigators used an EPA-free algal oil source of DHA, supplied by Martek. The study, authored by Dr. D. Kelly and associates, was conducted through the University of California Davis, Veterans Affairs of Northern California Health Care System and the US Department of Agriculture. Martek also contributed a portion of the funding for the study.

"The body of research supporting the health benefits of DHA for brain, eye and heart health throughout the lifecycle continues to grow," said Steve Dubin, CEO of Martek Biosciences.

Martek's life'sDHA(TM) is a vegetarian form of DHA omega-3, a long chain omega-3 fatty acid that serves as a primary building block for the brain and the eye and supports brain, eye and cardiovascular health throughout life. There is a large and growing body of scientific evidence demonstrating that people of all ages, from infants to aging adults, benefit from an adequate supply of DHA omega-3 in the diet. Scientific reviews have noted the importance of DHA omega-3 in proper brain and eye development and function, and there are clinical studies underway to evaluate its role in decreasing the prevalence of certain neurological disorders. Yet despite its importance, Americans have among the lowest dietary intakes of DHA omega-3 in the world.

Martek's life'sDHA(TM) is unique in the market because it is derived from a sustainable and vegetarian source. Made from microalgae under tightly controlled manufacturing conditions, life'sDHA(TM) is free of oceanic contaminants that may be present in certain fish or fish oils. Microalgae are the only vegetarian source of DHA omega-3, the key omega-3 for brain development and function.

Martek Biosciences Corporation (Nasdaq: MATK) is a leader in the innovation and development of DHA omega-3 products that promote health and wellness through every stage of life. The company produces life'sDHA(TM), a sustainable and vegetarian source of the omega-3 fatty acid DHA (docosahexaenoic acid), for use in foods, beverages, infant formula, and supplements. The company also produces life'sARA(TM) (arachidonic acid), an omega-6 fatty acid, from a sustainable, vegetarian source, for use in infant formula. For more information on Martek Biosciences Corporation, visit http://www.martek.com.

Sections of this release contain forward-looking statements. These statements are based upon numerous assumptions which Martek cannot control and involve risks and uncertainties that could cause actual results to differ. These statements should be understood in light of the risk factors set forth in the company's filings with the Securities and Exchange Commission, including, but not limited to, the company's Form 10-K for the fiscal year ended October 31, 2006 and other filed reports on Form 10-K, Form 10-K/A, Form 10-Q and Form 8-K.

Contact:

Philip Fass

Public Relations

(443) 542-2570

pfass@martek.com

Kyle Stults

Investor Relations

(410) 740-0081

investors@martek.com


'/>"/>
SOURCE Martek
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Gene study links endometriosis, infertility
2. Study reveals how stress can make you sick
3. Study points out that HIV vaccine may not be accepted easily
4. A new study surpasses Gene Therapy Hurdle
5. Tomato Sauce reduces Cancer Risk- Study
6. A question on study of Adult Stem Cell
7. Study on obesity and heart failure
8. National Lung Study in the process
9. Marijuana gateway theory strengthened by study of twins
10. Old theory of adaptation confirmed by new study
11. Study casts doubt on keyboard ills
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... 2016 , ... TopConsumerReviews.com recently awarded their highest five-star rating to Best Buy ... in the United States and Canada wear eyeglasses. Once considered to be a purely ... make a fashion statement. Even celebrities use glasses as a way of creating an ...
(Date:6/26/2016)... ... ... Brent Kasmer, a legally blind and certified personal trainer is helping to develop a weight ... app plans to fix the two major problems leading the fitness industry today:, ... program , They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, ... Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms ... Final Cut Pro X . Simply select a ProHand generator and drag it above ...
(Date:6/25/2016)... Canada (PRWEB) , ... June 25, 2016 , ... Conventional ... pursuit of success. In terms of the latter, setting the bar too high can ... risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Scientific Sessions in Dallas that it will receive two significant new grants to ... came as PHA marked its 25th anniversary by recognizing patients, medical professionals and ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 Capricor ... ), a biotechnology company focused on the discovery, ... that patient enrollment in its ongoing randomized HOPE-Duchenne ... exceeded 50% of its 24-patient target. Capricor expects ... third quarter of 2016, and to report top ...
(Date:6/23/2016)... BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia ... the company,s second affiliate in Latin America . ... ... Farma Colombia ... ...
(Date:6/23/2016)... Tenn. , June 23, 2016 /PRNewswire/ ... automating, integrating and transforming the patient payment ... of several innovative new products and services ... of its revenue cycle offerings. These award-winning ... more efficient workflows, remain compliant in an ...
Breaking Medicine Technology: